key: cord-0698674-n2kn7o67
authors: Dennis, A.; Wamil, M.; Kapur, S.; Alberts, J.; Badley, A.; Decker, G. A.; Rizza, S. A.; Banerjee, R.; Banerjee, A.
title: Multi-organ impairment in low-risk individuals with long COVID
date: 2020-10-16
journal: nan
DOI: 10.1101/2020.10.14.20212555
sha: 1dece768fdd7af284fb42df9c89abbff6f0f0184
doc_id: 698674
cord_uid: n2kn7o67

Background: Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection has disproportionately affected older individuals and those with underlying medical conditions. Research has focused on short-term outcomes in hospital, and single organ involvement. Consequently, impact of long COVID (persistent symptoms three months post-infection) across multiple organs in low-risk individuals is yet to be assessed. Methods: An ongoing prospective, longitudinal, two-centre, observational study was performed in individuals symptomatic after recovery from acute SARS-CoV-2 infection. Symptoms and organ function (heart, lungs, kidneys, liver, pancreas, spleen) were assessed by standardised questionnaires (EQ-5D-5L, Dyspnoea-12), blood investigations and quantitative magnetic resonance imaging, defining single and multi-organ impairment by consensus definitions. Findings: Between April and September 2020, 201 individuals (mean age 44 (SD 11.0) years, 70% female, 87% white, 31% healthcare workers) completed assessments following SARS-CoV-2 infection (median 140, IQR 105-160 days after initial symptoms). The prevalence of pre-existing conditions (obesity: 20%, hypertension: 6%; diabetes: 2%; heart disease: 4%) was low, and only 18% of individuals had been hospitalised with COVID-19. Fatigue (98%), muscle aches (88%), breathlessness (87%), and headaches (83%) were the most frequently reported symptoms. Ongoing cardiorespiratory (92%) and gastrointestinal (73%) symptoms were common, and 42% of individuals had ten or more symptoms. There was evidence of mild organ impairment in heart (32%), lungs (33%), kidneys (12%), liver (10%), pancreas (17%), and spleen (6%). Single (66%) and multi-organ (25%) impairment was observed, and was significantly associated with risk of prior COVID-19 hospitalisation (p<0.05). Interpretation: In a young, low-risk population with ongoing symptoms, almost 70% of individuals have impairment in one or more organs four months after initial symptoms of SARS-CoV-2 infection. There are implications not only for burden of long COVID but also public health approaches which have assumed low risk in young people with no comorbidities.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212555 doi: medRxiv preprint Definition of organ impairment 155 MRI-derived measurements from the heart, lungs, kidney, liver, pancreas and spleen were 156 compared with established reference ranges (Table S1) to determine impairment for each 157 organ. An individual organ was classified as impaired if at least one of the metrics calculated 158 for that organ was outside the reference range. Excessive organ fat was not considered as 159 an indicator of impairment on the assumption that this was likely pre-existing and thus 160 treated separately. Organ impairment was defined for each metric according to established 161 cut-offs (Table S1 ) and was grouped by evidence of: borderline or low ejection fraction and 162 evidence of myocarditis in the heart; reduced pulmonary dynamic measurements in the 163 lungs; elevated cortical T1 in the kidneys; borderline or definite inflammation in the liver and 164 pancreas; and splenomegaly from spleen length.

All statistical analyses were performed using R software (version 3.6.1) with a p-value less 168 than 0.05 considered statistically significant. Descriptive statistics were used to summarise 169 baseline participant characteristics. Mean and standard deviation (SD) were used to 170 describe normally distributed-continuous variables, median with interquartile range (IQR) for 171 non-normally distributed, and frequency and percentage for categorical variables.

Mean difference in quantitative organ metrics between hospitalised versus not hospitalised 174 were compared using the Wilcoxon test, and difference in the counts of the binary outcomes 175 of those with evidence of organ abnormalities compared using Fisher's test. Multi-organ 176 impairment was defined as impairment to ≥ 2 organs. Associations between multi-organ 177 impairment and symptoms, comorbidities and pre-existing risk factors were assessed using Spearman's correlation. Based on the observed differences between hospitalised and nonhospitalised groups, multivariate logistic regression models were used to assess risk factors CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212555 doi: medRxiv preprint older (p=0.001), had a higher proportion of non-white participants (p=0.038), and were more 195 likely to report 'inability to walk' (p=0.01) than non-hospitalised individuals. There were no 196 other significant differences between risk factors or symptoms reported between the groups.

The most commonly reported on-going symptoms (regardless of hospitalisation status) were 198 fatigue (98%), muscle ache (88%), shortness of breath (87%) and headache (83%) ( 

Single and multi-organ impairment 217 Impairment was present in the heart in 32% (myocarditis in 11%; systolic dysfunction in 218 23%), lungs in 33%, kidneys in 12%, liver in 10%, pancreas in 17%, and 6% had evidence of 219 splenomegaly (Table 2, Figure 2(b) ). 66% of individuals had impairment in one or more 220 organ systems. There was evidence of multi-organ impairment in 25% of individuals, with 221 varying degrees of overlap across multiple organs (Figure 1 and 3) . Organ impairment was 222 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212555 doi: medRxiv preprint more common in hospitalised versus non-hospitalised individuals. Measures of inflammation 223 in the kidneys and pancreas, and ectopic fat in the pancreas and liver, were also higher in 224 hospitalised individuals (all p <0.05) (Figure 2(b) ).

Association between symptoms, blood investigations and organ impairment 227 Figure 4 shows the percentage of reported symptoms in those with organ impairment (per 228 organ). Multi-organ involvement was associated with more serious symptoms (fatigue, CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212555 doi: medRxiv preprint following SARS-CoV2 infection, we had three major findings. First, in young individuals, impairment nor hospitalisation. Third, cardiac (myocarditis and systolic dysfunction) and lung 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212555 doi: medRxiv preprint although recent COVID-19 was associated with myocarditic changes, many non-infected 300 patients also showed these changes(30). We now add that one third of low-risk individuals CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212555 doi: medRxiv preprint broad inclusion criteria (e.g. SARS-CoV-2 testing by virus RNA, antibody or antigen), we characterise myocardial inflammation, allowing non-invasive tissue characterisation which 337 was previously evaluated as superior to gadolinium MRI for acute myocarditis(31).

We report baseline findings following SARS-CoV-2 infection. In our pragmatic study design, were added later to the protocol and follow up; they were not included from the outset to limit 346 interaction and exposure between trial team and patients. We did not include healthy 347 controls or MRI assessment of brain or muscle function. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212555 doi: medRxiv preprint reviewed articles, preprints, and research reports on long COVID syndrome and medium-414 and long-term impact of coronavirus disease 2019 (COVID-19), using the search terms 415 "coronavirus", "COVID-19", and similar terms, "organ impairment", "organ function" and 416 "morbidity", up to September 30, 2020. We found no prior studies of medium-or long-term 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. Table 1 : Baseline demographics and symptoms in 201 low-risk individuals with long-COVID. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212555 doi: medRxiv preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212555 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted October 16, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212555 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted October 16, 2020. . https://doi.org/10.1101/2020.10.14.20212555 doi: medRxiv preprint

World Health Organization. Clinical management of severe acute respiratory infection